Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations

References

• Cohen Aubart F, Lhote R, Amoura A, et al. Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Intern Med. 2020;288:356–362. doi:10.1111/joim.12991
   PubMed Web of Science ®Google Scholar
• Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011;197:W992–W1000. doi:10.2214/AJR.10.6198
   PubMed Web of Science ®Google Scholar
• Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3:1185–1192. doi:10.1158/2326-6066.CIR-15-0102
   PubMed Web of Science ®Google Scholar
• Danlos FX, Pagès C, Baroudjian B, et al. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149:e133–136. doi:10.1016/j.chest.2015.10.082
   PubMed Web of Science ®Google Scholar
• Cotliar J, Querfeld C, Boswell WJ, et al. Pembrolizumab-associated sarcoidosis. JAAD Case Rep. 2016;2:290–3. doi:10.1016/j.jdcr.2016.06.004
   PubMedGoogle Scholar
• Cousin S, Toulmonde M, Kind M, et al. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol. 2016;27:1178–1179. doi:10.1093/annonc/mdw125
   PubMed Web of Science ®Google Scholar
• Montaudié H, Pradelli J, Passeron T, et al. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol. 2017;176:1060–1063. doi:10.1111/bjd.14808
   PubMed Web of Science ®Google Scholar
• Hersey P, Karikios D, Shannon K, et al. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis. 2017;20:1277–1285. doi:10.1111/1756-185X.13076
   PubMed Web of Science ®Google Scholar
• Gayá García-Manso I, García Ródenas MDM, Barroso Medel ME, et al. Sarcoidosis-like granulomatous reaction associated with pembrolizumab immunotherapy. Arch Broncopneumol. (Engl Ed). 2018;54:592–593.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. doi:10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44. doi:10.1016/j.ejca.2017.05.032
   PubMed Web of Science ®Google Scholar
• Li Y, Flavell RR, Juarez R, et al. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clin Radiol. 2023;78:e131–e136. doi:10.1016/j.crad.2022.09.127
   PubMed Web of Science ®Google Scholar
• Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–2165.
   PubMed Web of Science ®Google Scholar
• Agostini C, Adami F, Semenzato G. New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol. 2000;12:71–6. doi:10.1097/00002281-200001000-00012
   PubMed Web of Science ®Google Scholar
• Zissel G, Prasse A, Muller-Quernheim J. Sarcoidosis: immunopathogenetic concepts. Semin Respir Crit Care Med. 2007;28:3–14. doi:10.1055/s-2007-970329
   PubMed Web of Science ®Google Scholar
• Wahlstrom J, Katchar K, Wigzell H, et al. Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med. 2001;163:115–121. doi:10.1164/ajrccm.163.1.9906071
   PubMed Web of Science ®Google Scholar
• Bobbio-Pallavicini E, Valsecchi C, Tacconi F, et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis. 1995;12:140–142.
   PubMedGoogle Scholar
• Chakravarty SD, Harris ME, Schreiner AM, et al. Sarcoidosis triggered by interferon- beta treatment of multiple sclerosis: a case report and focused Literature review. Semin Arthritis Rheum. 2012;42:206–212. doi:10.1016/j.semarthrit.2012.03.008
   PubMed Web of Science ®Google Scholar
• Park SD, Kim MS, Han MH, et al. Renal sarcoidosis-like reaction induced by PD-1 inhibitor treatment in non-small-cell lung cancer: a case report and literature review. Medicina. (Kaunas). 2023;59:991. doi:10.3390/medicina59050991
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhu W, Wu B, et al. Case report: hepatic sarcoid-like reaction associated with checkpoint inhibition in a NSCLC patient and a literature review. Front Oncol. 2022;12:824308. doi:10.3389/fonc.2022.824308
   PubMed Web of Science ®Google Scholar
• Tulbah RI, Rowe SP, Solnes LB, et al. Nivolumab-associated pulmonary and bone sarcoidosis in a patient with melanoma of unknown primary. Clin Nucl Med. 2019;44:e519. doi:10.1097/RLU.0000000000002724
   PubMed Web of Science ®Google Scholar
• Lu Y. FDG PET/CT course of pembrolizumab-associated multiorgan sarcoidosis. Clin Nucl Med. 2019;44:167–168. doi:10.1097/RLU.0000000000002408
   PubMed Web of Science ®Google Scholar
• Dunn-Pirio AM, Shah S, Eckstein C. Neurosarcoidosis following immune checkpoint inhibition. Case Rep Oncol. 2018;11:521–526. doi:10.1159/000491599
   PubMedGoogle Scholar
• Tan I, Malinzak M, Salama AKS. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. J Immunother Cancer. 2018;6:77. doi:10.1186/s40425-018-0390-2
   PubMed Web of Science ®Google Scholar
• Murphy KP, Kennedy MP, Barry JE O, et al. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat. 2014;37:351–353. doi:10.1159/000362614
   PubMedGoogle Scholar
• Chanson N, Ramos-Casals M, Pundole X, et al. Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation. Eur J Cancer. 2021;158:208–216. doi:10.1016/j.ejca.2021.05.041
   PubMed Web of Science ®Google Scholar
• Cabanié C, Ammari S, Hans S, et al. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: a case-control study. Eur J Cancer. 2021;156:46–59. doi:10.1016/j.ejca.2021.07.015
   PubMed Web of Science ®Google Scholar
• Torres-Jiménez J, Esteban-Villarrubia J, García-Abellás P, et al. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital. Clin Transl Oncol. 2021;23:1474–1480. doi:10.1007/s12094-020-02546-w
   PubMed Web of Science ®Google Scholar
• Chorti E, Kanaki T, Zimmer L, et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. Eur J Cancer. 2020;131:18–26. doi:10.1016/j.ejca.2020.02.024
   PubMed Web of Science ®Google Scholar
• Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 2018;28:230–6. doi:10.1097/CMR.0000000000000437
   PubMed Web of Science ®Google Scholar
• Arora K, Divatia MK, Truong L, et al. Sarcoid-like granulomas in renal cell carcinoma: the Houston Methodist Hospital experience. Ann Diagn Pathol. 2017;31:62–65. doi:10.1016/j.anndiagpath.2017.07.003
   PubMed Web of Science ®Google Scholar
• Sangoi AR, Maclean F, Mohanty S, et al. Granulomas associated with renal neoplasms: a multi-institutional clinicopathological study of 111 cases. Histopathology. 2022;80:922–927. doi:10.1111/his.14633
   PubMed Web of Science ®Google Scholar
• Tetzlaff MT, Nelson KC, Diab A, et al. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018;6:14. doi:10.1186/s40425-018-0323-0
   PubMed Web of Science ®Google Scholar